Literature DB >> 11979129

Streptococcus pneumoniae respiratory tract infections.

K P Klugman1, C Feldman.   

Abstract

This review describes recent contributions to our understanding of pneumococcal pneumonia. Two genes have been described that encode enzymes involved with the biosynthesis of muropeptides. These enzymes may be novel antibiotic targets. The clinical impact of increasing antibiotic resistance on the treatment of pneumonia is the particular focus of the review. As resistant strains are more commonly associated with severe infections in patients with underlying disease, the interpretation of an association of resistance with poor clinical outcome is complicated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11979129     DOI: 10.1097/00001432-200104000-00011

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  14 in total

1.  National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.

Authors:  L D Liebowitz; M Slabbert; A Huisamen
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

Review 2.  The genetic basis of pneumococcal and staphylococcal infections: inborn errors of human TLR and IL-1R immunity.

Authors:  Bertrand Boisson
Journal:  Hum Genet       Date:  2020-01-24       Impact factor: 4.132

3.  MKP1 regulates the induction of MUC5AC mucin by Streptococcus pneumoniae pneumolysin by inhibiting the PAK4-JNK signaling pathway.

Authors:  Un-Hwan Ha; Jae Hyang Lim; Hyun-Joong Kim; Weihui Wu; Shouguang Jin; Haidong Xu; Jian-Dong Li
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

4.  Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection.

Authors:  Keer Sun; Sharon L Salmon; Steven A Lotz; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

5.  Differences in antibiotic-induced oxidative stress responses between laboratory and clinical isolates of Streptococcus pneumoniae.

Authors:  Bédis Dridi; Andréanne Lupien; Michel G Bergeron; Philippe Leprohon; Marc Ouellette
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 6.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae.

Authors:  Gregory T Robertson; Jingyong Zhao; Bhushan V Desai; William H Coleman; Thalia I Nicas; Raymond Gilmour; Leo Grinius; Donald A Morrison; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

8.  Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling.

Authors:  Tomoaki Koga; Jae Hyang Lim; Hirofumi Jono; Un Hwan Ha; Haidong Xu; Hajime Ishinaga; Saori Morino; Xiangbin Xu; Chen Yan; Hirofumi Kai; Jian-Dong Li
Journal:  J Biol Chem       Date:  2008-03-10       Impact factor: 5.157

9.  Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence.

Authors:  Gregory T Robertson; Wai-Leung Ng; Joseph Foley; Raymond Gilmour; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2002-07       Impact factor: 3.490

Review 10.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.